Mary Elliott‐Davey

Statistics

Publications

Citations

995

H-Index

Active since

2019

Affiliations

Amgen (United States)(Current)

Amgen (United Kingdom)

Thrombolysis in Myocardial Infarction Study Group

Brigham and Women's Hospital

Harvard University

Mary Elliott‐Davey is an author at Amgen (United States) specializing in clinical pharmacology, cardiovascular disease, and cardiovascular pharmacotherapy.

Publications per year

2019–2024

Publications

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Michelle L. O’Donoghue, Robert P. Giugliano, Stephen D. Wiviott et al. · Circulation · 2022 · 380 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Michael J. Koren, Patrick M. Moriarty, Seth J. Baum et al. · Nature Medicine · 2022 · 226 citations

Life Sciences, Molecular Biology, Molecular Pharmaceutics +11

Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

Prakriti Gaba, Michelle L. O’Donoghue, Jeong‐Gun Park et al. · Circulation · 2023 · 173 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study

Robert S. Rosenson, Martha L. Daviglus, Yehuda Handelsman et al. · Diabetologia · 2019 · 71 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies

Peter P. Tóth, Steven R. Jones, Maria Laura Monsalvo et al. · Journal of the American Heart Association · 2020 · 35 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

1–5 of 9